Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

National Products Association To Supreme Court: Risk-Benefit Standard Would “Unravel” Dietary Supplement Act

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's risk-benefit standard to determine product adulteration violates Dietary Supplement Health and Education Act "and poses a significant threat" to dietary supplement firms, trade group says in amicus curiae brief.

You may also be interested in...



It's Complicated: FDA Prohibits CBD In Supplements, Enforcement Priority On Disease Claims

As FDA announces its first-ever approval of a drug that contains a substance derived from marijuana, officials say the agency's policy that prohibits CBD's use in dietary supplements or food will not change. They also say, however, that FDA's priority for enforcement actions against dietary supplements containing CBD, an extract from cannabis and hemp plants, will remain on products marketed with drug or disease claims.

Blame China? Experts Advise Congress, Industry Take A Wider View

The global scope of food safety is becoming apparent, and recent problems with products imported from China are but a part of U.S. food safety concerns, industry experts say

Blame China? Experts Advise Congress, Industry Take A Wider View

The global scope of food safety is becoming apparent, and recent problems with products imported from China are but a part of U.S. food safety concerns, industry experts say

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel